CO2018000236A2 - Composición de fluido peritoneal que comprende un agente potenciador de la biocompatibilidad y un sacárido - Google Patents

Composición de fluido peritoneal que comprende un agente potenciador de la biocompatibilidad y un sacárido

Info

Publication number
CO2018000236A2
CO2018000236A2 CONC2018/0000236A CO2018000236A CO2018000236A2 CO 2018000236 A2 CO2018000236 A2 CO 2018000236A2 CO 2018000236 A CO2018000236 A CO 2018000236A CO 2018000236 A2 CO2018000236 A2 CO 2018000236A2
Authority
CO
Colombia
Prior art keywords
saccharide
enhancing agent
fluid composition
peritoneal fluid
biocompatibility
Prior art date
Application number
CONC2018/0000236A
Other languages
English (en)
Spanish (es)
Inventor
Guido Grentzmann
Original Assignee
Opterion Health Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opterion Health Ag filed Critical Opterion Health Ag
Publication of CO2018000236A2 publication Critical patent/CO2018000236A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004Monosaccharides having only carbon, hydrogen and oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016Disaccharides, e.g. lactose, lactulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
    • A61M1/287Dialysates therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00Special media to be introduced, removed or treated
    • A61M2202/0021Special media to be introduced, removed or treated removed from and reintroduced into the body, e.g. after treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00Special media to be introduced, removed or treated
    • A61M2202/04Liquids
    • A61M2202/0413Blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)
CONC2018/0000236A 2015-07-20 2018-01-12 Composición de fluido peritoneal que comprende un agente potenciador de la biocompatibilidad y un sacárido CO2018000236A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15177544.2A EP3120842A1 (en) 2015-07-20 2015-07-20 Peritoneal therapeutic fluid
PCT/EP2016/067186 WO2017013120A1 (en) 2015-07-20 2016-07-19 Peritoneal therapeutic fluid

Publications (1)

Publication Number Publication Date
CO2018000236A2 true CO2018000236A2 (es) 2018-06-12

Family

ID=53785450

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0000236A CO2018000236A2 (es) 2015-07-20 2018-01-12 Composición de fluido peritoneal que comprende un agente potenciador de la biocompatibilidad y un sacárido

Country Status (23)

Country Link
US (2) US20180221303A1 (https=)
EP (2) EP3120842A1 (https=)
JP (1) JP6448847B2 (https=)
KR (2) KR20180048577A (https=)
CN (2) CN107921009B (https=)
AU (1) AU2016296216B2 (https=)
BR (1) BR112018001005B1 (https=)
CA (1) CA2990532C (https=)
CO (1) CO2018000236A2 (https=)
CY (1) CY1124467T1 (https=)
DK (1) DK3324951T3 (https=)
ES (1) ES2880796T3 (https=)
HR (1) HRP20211319T1 (https=)
HU (1) HUE055208T2 (https=)
LT (1) LT3324951T (https=)
MX (1) MX387020B (https=)
PL (1) PL3324951T3 (https=)
PT (1) PT3324951T (https=)
RS (1) RS62142B1 (https=)
RU (1) RU2718908C2 (https=)
SI (1) SI3324951T1 (https=)
SM (1) SMT202100428T1 (https=)
WO (1) WO2017013120A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3381484A1 (en) * 2017-03-31 2018-10-03 Opterion Health AG Carbohydrate composition for dialysis
CN108310005A (zh) * 2018-04-18 2018-07-24 浙江天瑞药业有限公司 一种抗腹膜纤维化的腹膜透析液
US12252505B2 (en) 2018-10-16 2025-03-18 President And Fellows Of Harvard College SIRT1 activating compounds
WO2025265015A1 (en) * 2024-06-20 2025-12-26 Barinta Therapeutics, Inc. Flavylium cations and electrolyte complexes thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2155910C (en) * 1995-08-11 1999-12-14 George Wu Biocompatible aqueous solution for use in continuous ambulatory peritoneal dialysis
IL147500A0 (en) * 1999-08-10 2002-08-14 Ml Lab Plc Method for delivery of therapeutic agents using a solution of dextrin
ATE311203T1 (de) * 1999-10-15 2005-12-15 Dow Global Technologies Inc Dialyselösung die polyglycol als osmotischen mittels enthält
JP4882054B2 (ja) * 2000-09-13 2012-02-22 独立行政法人科学技術振興機構 腹膜透析液およびその調製法
WO2003024391A2 (en) * 2001-08-16 2003-03-27 Mucosal Therapeutics, Inc. Treatment and prevention of mucositis in cancer patients
GB0200704D0 (en) * 2002-01-14 2002-02-27 Britannia Pharmaceuticals Ltd Use of phospholipids in peritoneal dialysis
ITRM20020562A1 (it) * 2002-11-06 2004-05-07 Sigma Tau Ind Farmaceuti Uso del resveratrolo per la preparazione di un medicamento utile per il trattamento delle infezioni da virus dell'influenza.
SE524530C2 (sv) * 2002-12-10 2004-08-24 Gambro Lundia Ab Metod för att framställa en medicinsk lösning för peritonealdialys där en lösning innehållandes ett eller flera acetylerade eller deacetylerade aminosocker värme- eller strålningssteriliseras med bestämda pH-värden och med bestämda viktsprocent för att undvika att cytotoxiska produkter bildas.
EP1684772A1 (en) * 2003-11-17 2006-08-02 Braintree Laboratories, Inc. Therapeutic peg solution concentrate
US7498341B2 (en) 2004-01-31 2009-03-03 Sanofi Aventis Deutschland Gmbh Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7384558B2 (en) 2004-07-26 2008-06-10 Baxter International Inc. Compositions capable of inhibiting reactive oxygen and carbonyl species
US20060292099A1 (en) * 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
WO2007049796A2 (en) 2005-10-26 2007-05-03 Kao Corporation Resveratrol and/or grape leaf extract as i. a. endurance improver, anti-aging agent, muscle strength improver
US20090035240A1 (en) * 2007-07-31 2009-02-05 Maes Daniel H Aqueous Based Cosmetic Compositions Containing Resveratrol Derivatives And An Aqueous Phase Structuring Agent
ES2685094T3 (es) * 2007-07-31 2018-10-05 Elc Management Llc Composiciones cosméticas que contienen resveratrol
CA2748344A1 (en) * 2008-11-26 2010-06-03 Lipoprotein Technologies, Inc. Enhanced bioactive formulations of resveratrol
CN105193777B (zh) * 2009-01-19 2019-06-28 利科雷德有限公司 类胡萝卜素和多酚的协同组合
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
ES2365429B1 (es) * 2010-03-05 2012-09-06 Universidad De Castilla De La Mancha Solucion para dialisis peritoneal
EP2609918A1 (en) * 2011-12-27 2013-07-03 Zytoprotec GmbH Peritoneal dialysis fluid comprising a GSK-3 inhibitor
WO2013159188A1 (en) * 2012-04-24 2013-10-31 The University Of British Columbia Polymer-based dialysate
EP2695606A1 (en) * 2012-08-09 2014-02-12 ETH Zürich Liposome composition for peritoneal dialysis
ITRM20130135A1 (it) * 2013-03-06 2014-09-07 Michele Azzolini Nuovi derivati del resveratrolo.
CN103330715B (zh) * 2013-07-01 2015-09-02 华仁药业股份有限公司 一种抗腹膜纤维化的腹膜透析液

Also Published As

Publication number Publication date
RU2018106122A3 (https=) 2019-10-10
EP3324951A1 (en) 2018-05-30
ES2880796T3 (es) 2021-11-25
AU2016296216A1 (en) 2017-12-14
US20180221303A1 (en) 2018-08-09
CN107921009A (zh) 2018-04-17
KR20190025759A (ko) 2019-03-11
BR112018001005A2 (pt) 2022-09-06
AU2016296216B2 (en) 2019-05-02
JP6448847B2 (ja) 2019-01-09
MX2018000336A (es) 2018-05-22
CY1124467T1 (el) 2022-07-22
JP2018522894A (ja) 2018-08-16
CA2990532A1 (en) 2017-01-26
EP3120842A1 (en) 2017-01-25
BR112018001005B1 (pt) 2023-11-28
PL3324951T3 (pl) 2021-12-13
SI3324951T1 (sl) 2021-09-30
CA2990532C (en) 2020-07-14
RU2018106122A (ru) 2019-08-20
HRP20211319T1 (hr) 2021-11-26
KR20180048577A (ko) 2018-05-10
RS62142B1 (sr) 2021-08-31
US20200022926A1 (en) 2020-01-23
MX387020B (es) 2025-03-19
SMT202100428T1 (it) 2021-09-14
US11160766B2 (en) 2021-11-02
RU2718908C2 (ru) 2020-04-15
HUE055208T2 (hu) 2021-11-29
CN107921009B (zh) 2020-12-11
DK3324951T3 (da) 2021-08-23
KR102266889B1 (ko) 2021-06-18
PT3324951T (pt) 2021-07-20
EP3324951B1 (en) 2021-05-26
CN110075307A (zh) 2019-08-02
WO2017013120A1 (en) 2017-01-26
HK1251176A1 (zh) 2019-01-25
LT3324951T (lt) 2021-07-26

Similar Documents

Publication Publication Date Title
MA42268A (fr) Compositions antimicrobiennes contenant des cannabinoïdes
CO2018000236A2 (es) Composición de fluido peritoneal que comprende un agente potenciador de la biocompatibilidad y un sacárido
BR112019023059A2 (pt) composições de limpeza melhoradas
EA201890926A1 (ru) ТРИАЗОЛОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ
MX390130B (es) Derivado de metil-mentol y composicion de agente refrescante que lo contiene.
CL2017001087A1 (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
EP3463360A4 (en) ATROPINE-BASED AQUEOUS COMPOSITION
TW201613806A (en) Water-soluble packaging film
EA201692241A1 (ru) Контейнер, индикаторное устройство и небулайзер
BR112017009467A2 (pt) composição de limpeza
MX2017003205A (es) Composiciones antimicrobianas y sus metodos de uso.
EA201791174A1 (ru) Антимикотическое соединение
MX371214B (es) Composición cosmética de filtro solar.
EP3513662A4 (en) A LIQUID FLAVORING INGREDIENT
MX384185B (es) Composicion en forma de emulsion de aceite en agua que comprende semillas molidas en mostaza blanca o amarilla.
CL2017001039A1 (es) Composiciones anti-transpirantes anhidras
MX2018002015A (es) Composicion de absorcion percutanea.
EA202091456A1 (ru) Мононитрат моноацетата пропандиола
MX376087B (es) Inhibidores macrocíclicos de cinasa rip2.
MX2014009244A (es) Una composicion y uso de la misma en el tratamiento de ragades anales.
PH12017500516A1 (en) Compositions
MX2017003604A (es) Solucion de dialisis.
CL2018001286A1 (es) Solución acuosa de peróxido de hidrógeno que comprende un estabilizante específico
EP3641781A4 (en) LIPOLYTIC COMPOSITION WITH PHOSPHOLINE DERIVATIVES
EA201591389A1 (ru) Косметические композиции с трициклодеканамидами